Introduction {#jcmm13096-sec-0001}
============

NOD and hypertension often co‐existed, and thereby, the risk of cardiovascular diseases is substantially increased [1](#jcmm13096-bib-0001){ref-type="ref"}, [2](#jcmm13096-bib-0002){ref-type="ref"}. And previous evidence showed that this clinical dilemma was associated with an increased risk of hepatitis C virus infection and graft rejection and loss and thereby affected patient survival quality [3](#jcmm13096-bib-0003){ref-type="ref"}. Also, it was reported that diabetes may be prevented by renin--angiotensin blockers [4](#jcmm13096-bib-0004){ref-type="ref"}, [5](#jcmm13096-bib-0005){ref-type="ref"}. Recently, a number of trials on antihypertensive medications such as angiotensin‐converting enzyme inhibitors (ACEIs), ARBs, CCBs, diuretics and β‐blockers have explored whether these medications influenced NOD development [2](#jcmm13096-bib-0002){ref-type="ref"}, [6](#jcmm13096-bib-0006){ref-type="ref"}, [7](#jcmm13096-bib-0007){ref-type="ref"}.

Studies showed that ACEI or ARB could reduce the incidence of NOD in patients [8](#jcmm13096-bib-0008){ref-type="ref"}. ACEI therapy contributed to significant reduction compared with diuretics and β‐blockers [9](#jcmm13096-bib-0009){ref-type="ref"}, and it is potentially effective in reducing hypertension and cardiovascular risks [9](#jcmm13096-bib-0009){ref-type="ref"}. ARB is an antihypertensive agent which is able to reduce NOD development by enhancing the insulin sensitivity [10](#jcmm13096-bib-0010){ref-type="ref"}. However, it did not improve clinical outcome of cardiovascular diseases and no significant evidence was revealed from former trials [11](#jcmm13096-bib-0011){ref-type="ref"}.

Clinical trials reviewed that the use of valsartan in patients with cardiovascular disease resulted in a 14% reduction in NOD, while no significant therapeutic improvement for cardiovascular disease was confirmed [12](#jcmm13096-bib-0012){ref-type="ref"}. CCB could significantly reduce the incidence of NOD, and CCB combined with ARB had metabolically neutral effects [13](#jcmm13096-bib-0013){ref-type="ref"}. Effects of β‐blockers on NOD patient are controversial which might contribute to a reduced mortality and morbidity of heart failure among patients with NOD [14](#jcmm13096-bib-0014){ref-type="ref"}, while it might trigger the development of NOD [6](#jcmm13096-bib-0006){ref-type="ref"}. It was also indicated that the use of diuretic is associated with a decreased incidence of NOD [15](#jcmm13096-bib-0015){ref-type="ref"} and prolonged diuretic treatment may result in an increased fasting glucose [15](#jcmm13096-bib-0015){ref-type="ref"}. In addition, the overall glycemic status was affected when both diuretics and β‐blockers are combined together [15](#jcmm13096-bib-0015){ref-type="ref"}. However, a study based on Indian population suggested that diuretics might increase the risk of NOD; that is, hypertensive patients treated with β‐blockers and diuretics exhibited higher incidence of diabetes mellitus [13](#jcmm13096-bib-0013){ref-type="ref"}.

Although previous meta‐analyses concluded that some antihypertensive medications were effective in NOD prevention, uncertain and controversy still remained to be clarified [4](#jcmm13096-bib-0004){ref-type="ref"}, [8](#jcmm13096-bib-0008){ref-type="ref"}, [9](#jcmm13096-bib-0009){ref-type="ref"}, [10](#jcmm13096-bib-0010){ref-type="ref"}, [16](#jcmm13096-bib-0016){ref-type="ref"}, [17](#jcmm13096-bib-0017){ref-type="ref"}, [18](#jcmm13096-bib-0018){ref-type="ref"}, [19](#jcmm13096-bib-0019){ref-type="ref"}, [20](#jcmm13096-bib-0020){ref-type="ref"}, [21](#jcmm13096-bib-0021){ref-type="ref"}, [22](#jcmm13096-bib-0022){ref-type="ref"}, [23](#jcmm13096-bib-0023){ref-type="ref"}, [24](#jcmm13096-bib-0024){ref-type="ref"}, besides, meta‐analyses were limited by few trials with direct comparisons between two treatments. Instead, a network meta‐analysis (NMA) can be conducted if both treatments have been compared to a common comparator. Formally, NMA can be defined as a statistical combination of all available evidence for an outcome from several studies across multiple treatments to generate estimates of pairwise comparison of each intervention to every other intervention within a network [25](#jcmm13096-bib-0025){ref-type="ref"}. As a result, we performed this NMA to compare the relative effectiveness of several antihypertensive medications including ACEIs (enalapril, lisinopril, perindopril, quinapril, ramipril, trandolapril), ARBs (include candesartan, losartan, telmisartan, valsartan), CCBs (amlodipine, verapamil), diuretics (bendrofluazide, chlorthalidone, hydrochlorothiazide) and β‐blockers (atenolol, propranolol).

Materials and methods {#jcmm13096-sec-0002}
=====================

Data search {#jcmm13096-sec-0003}
-----------

PubMed and Embase were searched, and studies from January 1985 up to June 2016 were identified to evaluate the efficacy of ACEIs, ARBs, CCBs, β‐blockers and diuretic. ARBs, ACEIs, CCBs, β‐blockers or diuretics and individual agent names within the medication classes were combined with 'diabetes', 'pre‐diabetes', 'new‐onset diabetes mellitus', 'new‐onset diabetes', 'NOD', 'hypertension', 'high risk', and 'randomized, controlled, trials''. Reference lists of identified articles including previous meta‐analyses and reviews were evaluated for additional relevant studies and information.

Selection criteria {#jcmm13096-sec-0004}
------------------

Studies were included if they fulfilled all the criteria as following: (*i*) comparison among ARBs, ACEIs, CCBs, β‐blockers, diuretics and PCB or other routine treatments; (*ii*) inclusion of individuals with hypertension or other high‐risk factors; (*iii*) the incidence of NOD as primary end‐point; (*iv*) average follow‐up over 1 year, recruiting more than 100 patients. Trials which did not meet above requirements were excluded.

Data extraction and quality assessment {#jcmm13096-sec-0005}
--------------------------------------

For each trial, all data derived from the published tables or texts were tabulated into a Microsoft Excel spreadsheet and the corresponding study characteristics were reviewed. In all data derived from each trial, we included total number of patients (overall population), number of patients with NOD at baseline, type and dosage of medications (ARBs, ACEIs, CCBs, β‐blockers, diuretics), follow‐up duration and other key study information.

Statistical analysis {#jcmm13096-sec-0006}
--------------------

The incidence of NOD was treated as a dichotomous variable and assessed by odds ratios (ORs) with 95% confidential intervals (CIs) for six antihypertensive. Then, a subgroup analysis was conducted to compare the efficacy of specific drugs using NMA. Pooled ORs were calculated using the DerSimonian and Laird random‐effects model [26](#jcmm13096-bib-0026){ref-type="ref"} or the Mantel--Haenszel fixed‐effects model [27](#jcmm13096-bib-0027){ref-type="ref"}, depending on the heterogeneity of treatment effects across studies. Bayesian statistical model was used. The percentage variability of the pooled ORs attributable to heterogeneity among the selected studies was quantified using the *I* ^2^ statistic test [28](#jcmm13096-bib-0028){ref-type="ref"}. Typically, values above 50% were deemed to suggest large between‐study heterogeneity. Under such a circumstance, the random‐effects model was used to improve accuracy of research. Ranking of medication with respect to the effectiveness of NOD prevention was achieved using the surface under the cumulative ranking area (SUCRA). A higher SUCRA value indicates a more desirable property with respect to a certain end‐point. Statistical analyses were conducted using R version 3.1.3 (R Project for Statistical Computing, Vienna, Austria). *P \<* 0.05 was considered significantly different.

Results {#jcmm13096-sec-0007}
=======

Study selection {#jcmm13096-sec-0008}
---------------

As schematically shown in Figure [1](#jcmm13096-fig-0001){ref-type="fig"}, among the 396 potentially eligible trials, 52 duplicates were removed, 297 studies were excluded by screening titles and abstracts and 24 full‐text articles were ruled out as their outcome did not contain NOD data or medications were not properly compared. Thus, there were 23 totally randomized clinical trials, including a total of 224,832 patients, following as the selected criteria and selected in this meta‐analysis study [29](#jcmm13096-bib-0029){ref-type="ref"}, [30](#jcmm13096-bib-0030){ref-type="ref"}, [31](#jcmm13096-bib-0031){ref-type="ref"}, [32](#jcmm13096-bib-0032){ref-type="ref"}, [33](#jcmm13096-bib-0033){ref-type="ref"}, [34](#jcmm13096-bib-0034){ref-type="ref"}, [35](#jcmm13096-bib-0035){ref-type="ref"}, [36](#jcmm13096-bib-0036){ref-type="ref"}, [37](#jcmm13096-bib-0037){ref-type="ref"}, [38](#jcmm13096-bib-0038){ref-type="ref"}, [39](#jcmm13096-bib-0039){ref-type="ref"}, [40](#jcmm13096-bib-0040){ref-type="ref"}, [41](#jcmm13096-bib-0041){ref-type="ref"}, [42](#jcmm13096-bib-0042){ref-type="ref"}, [43](#jcmm13096-bib-0043){ref-type="ref"}, [44](#jcmm13096-bib-0044){ref-type="ref"}, [45](#jcmm13096-bib-0045){ref-type="ref"}, [46](#jcmm13096-bib-0046){ref-type="ref"}, [47](#jcmm13096-bib-0047){ref-type="ref"}, [48](#jcmm13096-bib-0048){ref-type="ref"}, [49](#jcmm13096-bib-0049){ref-type="ref"}, [50](#jcmm13096-bib-0050){ref-type="ref"}, [51](#jcmm13096-bib-0051){ref-type="ref"}.

![Study flow diagram. NOD: new‐onset diabetes.](JCMM-21-1742-g001){#jcmm13096-fig-0001}

Population characteristics {#jcmm13096-sec-0009}
--------------------------

The general characteristics of the identified trials are shown in Table [1](#jcmm13096-tbl-0001){ref-type="table-wrap"}. Eight trials were designed to compare ARBs‐based treatments against PCB; six trials were aimed to compare ACEIs‐based treatments against PCB; and nine trials were designed to compare to each other among the five different treatments, namely ARBs, ACEIs, CCBs, β‐blockers or diuretic. A total of 224,832 hypertensive patients were involved in our study. A total of 53,719 (23.9%) patients were treated by PCB, 42,422 (18.9%) patients were randomized to receive ARBs, 39,899 (17.7%) patients received CCBs, 33,645 (15.0%) patients were treated by β‐blockers, 29,259 (13.0%) were treated by ACEIs and 25,888 (11.5%) were treated by diuretics. Network plots of six different kinds of medications and 18 agents were shown in Figure [2](#jcmm13096-fig-0002){ref-type="fig"} and Figure S1. The mean age of these identified patients ranged from 51 to 72 years, and the duration was over an average follow‐up period of 3.9 ± 1.0 years.

###### 

Characteristics of studies included in the network meta‐analysis

  Study                      Blinding       Duration (years)   Treatment class          Treatment drugs                                          Mean age    BP (mmHg)    Sample size
  -------------------------- -------------- ------------------ ------------------------ -------------------------------------------------------- ----------- ------------ ------------------
  MRC trail,1985             Single‐blind   4.9                β‐Blocker/diuretic/PCB   Propranolol/bendrofluazide/Placebo                       51/51/51    158/98       4403/4297/8654
  Wilhelmsen,1987            --             3.8                β‐Blocker/diuretic       Atenolol/metoprolol/bendrofluazide/hydrochlorothiazide   52.3/52.2   166/107      3727/3297
  Yusuf,2001                 Double‐blind   4.5                ACEI/PCB                 Ramipril/placebo                                         66.3/65.9   136.4/78.2   2837/2883
  ALLHAT officers,2002       Double‐blind   4.9                ACEI/diuretic/CCB        Lisinopril/chlorthalidone/amlodipine                     67/67/67    146/84       9054/15,255/9048
  Lindholm,2002              Double‐blind   4.8                ARB/β‐blocker            Losartan/atenolol                                        66.9/66.9   174.3/97.9   4605/4588
  Fox,2003                   Double‐blind   4.3                ACEI/PCB                 Perindopril/placebo                                      60/60       137/82       6110/6108
  Vermes,2003                Double‐blind   2.9                ACEI/PCB                 Enalapril/placebo                                        56.1/56.8   127.4/77.8   153/138
  Wing,2003                  --             4.1                ACEI/diuretic            Enalapril/hydrochlorothiazide                            72/71.9     167/91       3044/3039
  Pfeffer,2003               Double‐blind   3.1                ARB/PCB                  Candesartan/placebo                                      65.9/66     130.6/76.6   3803/3796
  Littell,2003               Double‐blind   3.7                ARB/PCB                  Candesartan/placebo                                      76.4/76.4   166/90.3     2477/2460
  Granger,2003               Double‐blind   2.8                ARB/PCB                  Candesartan/placebo                                      66.3/66.8   127/78       1013/1015
  Yusuf,2003                 Double‐blind   3.1                ARB/PCB                  Candesartan/placebo                                      67.2/67.1   130.6/76.6   1514/1509
  Pepine,2003                --             2.7                CCB/β‐blocker            Verapamil/atenolol                                       66/66       149.5/86.3   11,267/11,309
  McMurray,2003              Double‐blind   3.4                ARB/PCB                  Candesartan/placebo                                      64/64.1     166/90.3     1276/1272
  Braunwald,2004             Double‐blind   4.8                ACEI/PCB                 Trandolapril/placebo                                     64/64       134/78       4158/4132
  Julius,2004                Double‐blind   4.2                ARB/CCB                  Valsartan/amlodipine                                     67.2/67.3   154.5/87.4   7649/7596
  Dahlof,2005                Single‐blind   5.5                β‐Blocker/CCB            Atenolol/amlodipine                                      63/63       130/‐        9618/9639
  Dream Investigators,2006   Double‐blind   3                  ACEI/PCB                 Ramipril/placebo                                         54.7/54.7   136.1/83.4   2623/2646
  Yusuf,2008                 --             2.5                ARB/PCB                  Telmisartan/placebo                                      66.1/66.2   144.1/83.8   10,146/10,186
  Ogihara,2008               --             3.2                ARB/CCB                  Candesartan/amlodipine                                   63.8/63.9   162.5/91.6   2354/2349
  TRANSCEND,2008             Double‐blind   4.7                ARB/PCB                  Telmisartan/placebo                                      66.9/66.9   140.7/81.8   2954/2972
  Rouleau,2008               Double‐blind   2.95               ACEI/PCB                 Quinapril/placebo                                        61/61       122/70       1280/1273
  NAVIGAROR group,2010       Double‐blind   6                  ARB/PCB                  Valsartan/placebo                                        63.7/63.8   139.4/82.5   4631/4675

BP: blood pressure; PCB: placebo; ACEI: angiotensin converse enzyme inhibitor; CCB: calcium channel blockers; ARB: angiotensin II receptor blockers.
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![Network plot of eligible comparisons of categorized six different medications in NOD in the meta‐analysis. The width of the lines represents the total number of trials for each comparison. ACEIs: angiotensin converse enzyme inhibitors; ARBs: angiotensin II receptor blockers; CCBs: calcium channel blockers; NOD: new‐onset diabetes.](JCMM-21-1742-g002){#jcmm13096-fig-0002}

Incidence of NOD {#jcmm13096-sec-0010}
----------------

As shown in Table [2](#jcmm13096-tbl-0002){ref-type="table-wrap"}, both ACEIs and ARBs showed a significant decline in the incidence of NOD compared to PCB, (OR = 0.82, 95% CrI = 0.64--0.99; OR = 0.81, 95% CrI = 0.66--0.96).And diuretics were associated with a higher risk of NOD compared with PCB (OR = 1.44 95% CrI = 1.06--1.94). Treatment of β‐blockers and diuretics showed a higher incidence of NOD than ACEIs (OR = 1.38, 95% CrI = 1.00--1.93; OR = 1.75, 95% CrI = 1.31--2.41), whereas β‐blockers, CCBs and diuretics also showed a significant elevation in the incidence of NOD compared to ARBs (OR = 1.40, 95% CrI = 1.04--1.88; OR = 1.33, 95% CrI = 1.00--1.75; OR = 1.78, 95% CrI = 1.30--2.46). Figure [3](#jcmm13096-fig-0003){ref-type="fig"} illustrated the forest plot of network results.

###### 

Results of six interventions for the incidence of new‐onset diabetes (NOD) from network meta‐analysis

  Treatment    PCB                     Diuretics               CCBs                    β‐Blockers              ARBs                    ACEIs
  ------------ ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- -----------------------
  PCB          **PCB**                 **1.44 (1.06, 1.94)**   1.07 (0.80, 1.43)       1.13 (0.83, 1.53)       **0.81 (0.67, 0.96)**   **0.82 (0.65, 1.00)**
  Diuretics    **0.70 (0.52, 0.95)**   **Diuretics**           0.74 (0.54, 1.03)       0.79 (0.57, 1.07)       **0.56 (0.41, 0.77)**   **0.57 (0.42, 0.76)**
  CCBs         0.94 (0.70, 1.26)       1.34 (0.97, 1.87)       **CCBs**                1.06 (0.80, 1.39)       **0.75 (0.57, 1.00)**   0.77 (0.56, 1.04)
  β‐Blockers   0.89 (0.65, 1.21)       1.27 (0.93, 1.76)       0.94 (0.72, 1.26)       **β‐Blockers**          **0.71 (0.53, 0.96)**   **0.73 (0.52, 1.00)**
  ARBs         **1.24 (1.04, 1.49)**   **1.78 (1.30, 2.46)**   **1.33 (1.00, 1.75)**   **1.40 (1.04, 1.88)**   **ARBs**                1.02 (0.77, 1.31)
  ACEIs        **1.22 (1.00, 1.54)**   **1.75 (1.31, 2.41)**   1.31 (0.97, 1.80)       **1.38 (1.00, 1.93)**   0.98 (0.76, 1.30)       **ACEIs**

Bold values mean statistic difference.
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![Forest plot for ARBs, ACEIs, CCBs, β‐blockers, diuretic or PCB‐based strategy on the incidence of NOD. ACEIs: angiotensin converse enzyme inhibitors; ARBs: angiotensin II receptor blockers; CCBs: calcium channel blockers; NOD: new‐onset diabetes.](JCMM-21-1742-g003){#jcmm13096-fig-0003}

Ranking of antihypertensive medications by SUCRA {#jcmm13096-sec-0011}
------------------------------------------------

The probability of six antihypertensive medications having specific rank (1--6) and the probability of three kinds of ARBs having each specific rank (1--4) for the incidence of NOD are presented in Figure [4](#jcmm13096-fig-0004){ref-type="fig"}. SUCRA showed that both ARBs (SUCRA = 0.894) and ACEIs (SUCRA = 0.880) exhibited distinct advantages compared to the other four treatments and diuretics (SUCRA = 0.022) exhibited the last least reliable performance in comparison with other medications. Candesartan was considered to be more desirable than other ARBs (Table [3](#jcmm13096-tbl-0003){ref-type="table-wrap"} and Table S1).

![Rank graphs showing the probability of six different kinds of medications having each specific rank (1--6) and the probability of three kinds of ARBs having each specific rank (1--4) for end‐points. Ranking suggests the probability to be the best intervention treatment, the second best and so on. Rank 1st is best and Rank 6th is worst.](JCMM-21-1742-g004){#jcmm13096-fig-0004}

###### 

Surface under the cumulative ranking curve (SUCRA) of 18 treatments according to NOD

  Classification   Drugs                 SUCRA   Mean rank
  ---------------- --------------------- ------- -----------
  ACEI             Enalapril             0.998   1
  ACEI             Ramipril              0.700   4
  ACEI             Quinapril             0.698   5
  ACEI             Trandolapril          0.661   7
  ACEI             Lisinopril            0.558   9
  ACEI             Perindopril           0.485   10
  ARB              Candesartan           0.735   3
  ARB              Telmisartan           0.675   6
  ARB              Valsartan             0.628   8
  ARB              Losartan              0.306   14
  β‐Blocker        Propranolol           0.475   11
  β‐Blocker        Atenolol              0.122   16
  CCB              Amlodipine            0.326   13
  CCB              Verapamil             0.059   17
  Diuretic         Hydrochlorothiazide   0.938   2
  Diuretic         Chlorthalidone        0.203   15
  Diuretic         Bendrofluazide        0.020   18
  Placebo          Placebo               0.424   12

John Wiley & Sons, Ltd

Assessing inconsistency between direct and indirect evidence {#jcmm13096-sec-0012}
------------------------------------------------------------

One fundamental assumption in our NMA is the adoption of a consistency model in which the extent of consistency is validated using the node splitting method. Results of direct, indirect and network comparisons of these interventions were displayed in node splitting forest plots as shown in Figure [5](#jcmm13096-fig-0005){ref-type="fig"} and a *P*‐value of less than 0.05 suggests potentially significant inconsistency and hence, the consistency model assumption may be violated. The inconsistency only exists in comparison between PCB and diuretics (*P*‐value = 0.001). As it is the only case in which potential significant inconsistency may arise from, we did not replace the consistency model in our NMA.

![Summarized results of direct and indirect comparisons between ARBs, ACEIs, CCBs, β‐blockers, diuretic or PCB‐based strategy on the incidence of NOD. ACEIs: angiotensin converse enzyme inhibitors; ARBs: angiotensin II receptor blockers; CCBs: calcium channel blockers; NOD: new‐onset diabetes.](JCMM-21-1742-g005){#jcmm13096-fig-0005}

Discussion {#jcmm13096-sec-0013}
==========

Patients with hypertension usually have a higher risk of NOD which may trigger cardiovascular diseases [52](#jcmm13096-bib-0052){ref-type="ref"}. Preventing NOD among patients with hypertension has been considered as a prioritized task by clinicians. Current antihypertensive medications are generally divided into several classes, namely thiazide diuretic, ACEIs, ARBs, CCBs and β‐blockers [53](#jcmm13096-bib-0053){ref-type="ref"}. In this study, we collected data from 23 NOD studies which investigated six antihypertensive medications in order to assess their efficacy with respect to NOD prevention. We aimed to provide conclusive evidence for ranking these medications so that potential guidance with respect to medication selection can be recommended to clinicians.

In this study, the results of NMA showed that patients treated by ARBs or ACEIs were associated with a reduced risk of NOD compared to those with PCB, while diuretic appeared to be ineffective with respect to NOD prevention. ARBs also exhibited a better performance with respect to NOD prevention compared to CCBs or β‐blockers. As suggested by the overall rank, both ARBs and ACEIs, especially enalapril and candesartan, were more preferable than other treatments and hydrochlorothiazide also exhibited a reliable performance in comparison with other agents.

Previous studies demonstrated that the renin--angiotensin system was activated in all insulin resistant states in which type II diabetes or hypertension may be involved [54](#jcmm13096-bib-0054){ref-type="ref"}. Blocking the RAS not only improved blood circulation and cellular ionic balance of pancreatic and skeletal muscle cells, but also enhanced the effects of peripheral insulin and insulin secretion by promoting the recruitment and differentiation of adipocytes in diabetes [55](#jcmm13096-bib-0055){ref-type="ref"}. Recent studies showed that hypertensive patients treated by ACEIs or ARB were associated with a lower risk of NOD or adverse cardiovascular events [56](#jcmm13096-bib-0056){ref-type="ref"}, [57](#jcmm13096-bib-0057){ref-type="ref"}, [58](#jcmm13096-bib-0058){ref-type="ref"} and such a mechanism may involve the improvements in both insulin sensitivity and secretion [59](#jcmm13096-bib-0059){ref-type="ref"}. However, ARBs and ACEIs have different mechanisms with respect to preventing insulin resistance. For instance, ACEIs inhibits the conversion from Ang I to Ang II and blocks the degradation of bradykinin whereas ARBs suppresses Ang II by selectively binding to the corresponding receptor site [60](#jcmm13096-bib-0060){ref-type="ref"}. In this study, both direct and indirect evidence confirmed that patients treated by ARBs or ACEIs were associated with a reduced risk of NOD compared to those with PCB, while diuretics appeared to be ineffective with respect to NOD prevention and ARBs also exhibited better performance with respect to NOD prevention compared to CCBs or β‐blockers. Compared to diuretics, ACEIs is potentially more cost‐effective for elderly hypertensive patients [1](#jcmm13096-bib-0001){ref-type="ref"}. The corresponding mechanism of ACEIs may be linked with the lack of major sympathoexcitatory effects improvements in insulin sensitivity [61](#jcmm13096-bib-0061){ref-type="ref"}.

Diuretics have been widely used for managing salt‐sensitive hypertension, and they are divided into diuretics, such as hydrochlorothiazide and thiazide‐like diuretics such as chlorthalidone and bendrofluazide [62](#jcmm13096-bib-0062){ref-type="ref"}. A recent study showed that hydrochlorothiazide was inferior to indapamide for improving endothelial functions and ventriculoarterial coupling in patients who suffered from both hypertension and diabetes [63](#jcmm13096-bib-0063){ref-type="ref"}. In this study, patients treated by ARBs or ACEIs were associated with a significant reduction in the incidence of NOD compared to those treated by bendrofluazide or chlorthalidone. However, patients treated by hydrochlorothiazide exhibited a significant reduction in the risk of NOD compared to those treated by ARBs, ACEIs, CCBs, β‐blockers or other diuretics except enalapril. CCBs and β‐blockers, as two other first‐line antihypertensive medications, are effective in preventing cardiovascular events [64](#jcmm13096-bib-0064){ref-type="ref"} and are generally prescribed by clinicians as hypertension therapies [65](#jcmm13096-bib-0065){ref-type="ref"}. It has been shown that CCBs or β‐blockers had mild or no impact on the risk of NOD [66](#jcmm13096-bib-0066){ref-type="ref"}. Results from our study indicated that patients treated by CCBs or β‐blockers seemed to have equivalent risk of NOD.

As the first Bayesian NMA, our study compared six antihypertensive medications that were used in hypertensive patients for preventing NOD and the corresponding data were synthesized from the current literature. However, a few limitations contained in this study should be concerned and addressed in the future. Firstly, there was significant variation in the number of studies with respect to each comparison. For instance, the number of studies which compared losartan, propranolol, chlorthalidone or bendrofluazide was significantly less than that of others and this may result in wide confidence interval for summary statistics when data were synthesized. Secondly, variation in the sample size and study duration within each individual study as well as variation in other study characteristics may cause significant heterogeneity and thereby pooling evidence from individual studies with significant heterogeneity may not be comparable.

For summary, both ARBs and ACEIs exhibited compelling results with respect to the prevention of NOD and such a trend is even more significant in patients treated by enalapril (ACEIs) or candesartan (ARBs). Apart from that, hydrochlorothiazide also exhibited reliable performance in comparison with other agents. Large‐scale randomized trials should be designed and implemented to confirm the above conclusions.
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###### 

**Figure S1.** Network plot of eligible studies comparing 18 agents included in six different kinds of medications in NOD. The width of the lines represents the total number of trials for each comparison.

###### 

Click here for additional data file.

###### 

**Table S1**. Results of 17 antihypertensive agents and placebo for the incidence of new onset diabetes (NOD) from net‐work meta‐analysis.

###### 

Click here for additional data file.
